Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC).
Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC).
复制标题
DOI：
10.1186/2162-3619-2-15
复制
发表时间：
2013-05-20
影响因子：
10.9
通讯作者：
Zhang JY
中科院分区：
文献类型：
--
作者：
Dai L;Lei N;Liu M;Zhang JY
由免疫系统的细胞和/或体液效应物识别的肿瘤相关抗原（TAA）是用于人类癌症的诊断和治疗方法的有吸引力的靶标。可以使用不同的方法来全面表征和验证所鉴定的TAA/抗TAA系统，其是癌症免疫诊断中的潜在生物标志物。肝细胞癌（HCC）是世界范围内最常见的癌症之一。肝癌在发现后一年内的高死亡率可能部分归因于缺乏能够早期发现的诊断方法。我们以前的研究表明，在从慢性肝病向HCC转变的过程中，可能出现新的自身抗体，这些抗体在癌前病变之前未被检测到。我们提出的假设是，向恶性肿瘤的转变可能与对某些细胞蛋白的自身抗体反应有关，这些蛋白可能在肿瘤发生中起一定作用。我们建议癌症患者的免疫系统以肿瘤相关抗原（TAAs）自身抗体的形式传递的信息应在更大程度上用于识别肿瘤发生的早期迹象。本文就TAA的重要特征及其自身抗体作为HCC免疫诊断和预后判断的生物标志物的可能性作一综述。
Tumor-associated antigens (TAAs) recognized by cellular and/or humoral effectors of the immune system are attractive targets for diagnostic and therapeutic approaches to human cancer. Different approaches can be used to comprehensively characterize and validate the identified TAA/anti-TAA systems, which are potential biomarkers in cancer immunodiagnosis. Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The high fatality rate of HCC within one year after its detection might be partly attributed to a lack of diagnostic methods that enable the early detection. Our previous studies have shown that novel autoantibodies can appear which are not detected prior to pre-malignant conditions during transition from chronic liver disease to HCC. The hypothesis we advance is the transition to malignancy can be associated with autoantibody response to certain cellular proteins that might have some role in tumorigenesis. We propose that the information that the cancer patient’s immune system is conveying in the form of autoantibodies to tumor-associated antigens (TAAs) should be utilized to a greater extent in identifying early signs of tumorigenesis. In this review, we will focus on the important features of TAA and the possibility that autoantibodies to TAAs can be used as biomarkers in immunodiagnosis and prognosis of HCC.